文献速递头颈部肿瘤放疗

HPV阳性口咽癌降强度放化疗后的功能结局:2期试验次要分析

Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-11-06

该2期试验次要分析评估了40例可评估的p16阳性III/IV期口咽鳞癌患者,接受诱导化疗后同步放化疗(54或60 Gy)的降强度方案。治疗前BMI正常者约18个月恢复至基线。

要点

  • 降强度放化疗后胃造瘘管放置率低(5%),6个月无肠内营养依赖。
  • 治疗前BMI正常者约18个月恢复至基线水平。

核心结论

  • 降强度放化疗可能改善功能结局,表现为胃造瘘管放置率和长期吞咽困难发生率相对较低。

研究设计与样本

  • 2期试验的次要分析,纳入p16阳性III或IV期口咽鳞癌且Zubrod体能状态0-1的患者。
  • 治疗方案为诱导化疗(紫杉醇175 mg/m2+卡铂AUC 6 mg/ml/min,每21天2周期),随后同步紫杉醇30 mg/m2每7天联合减量放疗54或60 Gy。

主要发现

  • 仅1例患者在治疗完成时BMI被认为不健康。
  • 治疗前BMI正常(18-25 kg/m2)的15例患者(38%)约18个月恢复至基线(平均BMI 23.2 kg/m2 vs 22.3 kg/m2;P=.09)。
  • 2例患者(5%)在治疗期间放置胃造瘘管。
  • 治疗结束后6个月无患者依赖肠内喂养管。

临床怎么用

  • 对于HPV阳性口咽癌患者,降强度放化疗可在不增加营养干预依赖的情况下维持较好功能结局。
  • 治疗前BMI正常者需关注约18个月的体重恢复过程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze functional outcomes for patients treated on a phase 2 trial of de-escalated chemoradiation therapy for human papillomavirus-positive oropharyngeal cancer. METHODS AND MATERIALS: Patient eligibility included p16-positive, stage III or IV oropharyngeal squamous cell carcinoma and a Zubrod performance status of 0 to 1. Treatment was induction chemotherapy with paclitaxel, 175 mg/m2, and carboplatin, area under the curve (AUC) of 6 mg/ml/min, for 2 cycles every 21 days, followed by concurrent paclitaxel, 30 mg/m2, every 7 days with dose-reduced radiation therapy of 54 or 60 Gy. Trends in body weight and body mass index (BMI) were analyzed with gastrostomy tube and narcotic use rates. Functional outcomes were assessed using the University of Washington Quality of Life Scale and the Functional Assessment of Cancer Therapy-Head and Neck Scale. RESULTS: Forty-five patients were registered, of whom 40 were evaluable. Only 1 patient had a BMI deemed unhealthy at the completion of treatment. For the 15 patients (38%) with a normal BMI (18-25 kg/m2) before treatment, recovery back to baseline occurred at approximately 18 months (average BMI, 23.2 kg/m2 vs 22.3 kg/m2; P=.09). In 2 patients (5%), gastrostomy tubes were placed during treatment. No patient was enteral feeding tube-dependent at 6 months after treatment. Ninety-five percent of patients tolerated a normal regular diet at last follow-up. CONCLUSIONS: De-escalated chemoradiation therapy may improve functional outcomes as indicated by the relatively low incidence of gastrostomy tube placement and long-term dysphagia. In patients with a normal BMI prior to chemoradiation therapy, BMI recovered to baseline levels.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hegde JV, Shaverdian N, Felix C, et al. Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2017. PMID: 29246721. doi:10.1016/j.ijrobp.2017.10.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。